Literature DB >> 33510884

Angiotensin receptor neprilysin inhibitor in inotrope dependent heart failure patients: A case series.

Sepideh Taghavi1, Maryam Chenaghlou2, Marzieh Mirtajaddini3, Ahmad Amin1, Nasim Naderi1.   

Abstract

Patients with advanced heart failure (HF) symptoms constitute stage D heart failure with high mortality and less response to conventional guideline directed medical therapies. These patients are subjected to receive non-medical therapies including heart transplant or mechanical circulatory support for increasing survival. Considering the low availability and serious complications of these strategies,effective medical therapies for this group of patients would be pivotal for decreasing mortality and morbidity of them. Angiotensin receptor neprilysin inhibitor (ARNI) is a class of drugs approved for ambulatory heart failure patients. ARNI use like other groups of heart failure drugs has not been fully evaluated in end-stage heart failure patients. Herein, we describe four inotrope-dependent heart failure patients. Initiation of ARNI in these patients, lead to discontinuation of inotrope and reducing the need for inotrope in the follow-up period.
© 2020 The Author(s).

Entities:  

Keywords:  Angiotensin Receptor Neprilysin Inhibitor; Heart Failure; Inotrope-Dependent; Stage D

Year:  2020        PMID: 33510884      PMCID: PMC7828763          DOI: 10.34172/jcvtr.2020.53

Source DB:  PubMed          Journal:  J Cardiovasc Thorac Res        ISSN: 2008-5117


  7 in total

1.  PIONEERing the In-Hospital Initiation of Sacubitril-Valsartan.

Authors:  John Jarcho
Journal:  N Engl J Med       Date:  2019-02-07       Impact factor: 91.245

2.  Safety and efficacy of sacubitril─valsartan in acute heart failure.

Authors:  Alexandra Le Bras
Journal:  Nat Rev Cardiol       Date:  2019-01       Impact factor: 32.419

3.  ARNI in cardiovascular disease: current evidence and future perspectives.

Authors:  Pramod Kumar Kuchulakanti
Journal:  Future Cardiol       Date:  2020-04-22

4.  Angiotensin Receptor-Neprilysin Inhibitor Therapy Reverses Pulmonary Hypertension in End-Stage Heart Failure Patients Awaiting Transplantation.

Authors:  Emily K Zern; Susan Cheng; Aaron M Wolfson; Michele A Hamilton; Michael R Zile; Scott D Solomon; Michelle M Kittleson
Journal:  Circ Heart Fail       Date:  2020-02-14       Impact factor: 8.790

5.  Left Ventricular Ejection Fraction Recovery in Patients with Heart Failure and Reduced Ejection Fraction Treated with Sacubitril/Valsartan.

Authors:  Pablo Díez-Villanueva; Lourdes Vicent; Francisco de la Cuerda; Alberto Esteban-Fernández; Manuel Gómez-Bueno; Javier de Juan-Bagudá; Ángel Manuel Iniesta; Ana Ayesta; Antonio Rojas-González; Ramón Bover-Freire; Diego Iglesias; Marcos García-Aguado; Jesús Ángel Perea-Egido; Jorge Salamanca; Manuel Martínez-Sellés
Journal:  Cardiology       Date:  2020-01-15       Impact factor: 1.869

6.  Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.

Authors:  Douglas L Mann; Stephen J Greene; Michael M Givertz; Justin M Vader; Randall C Starling; Andrew P Ambrosy; Palak Shah; Steven E McNulty; Claudius Mahr; Divya Gupta; Margaret M Redfield; Anuradha Lala; Gregory D Lewis; Selma F Mohammed; Nisha A Gilotra; Adam D DeVore; Eiran Z Gorodeski; Patrice Desvigne-Nickens; Adrian F Hernandez; Eugene Braunwald
Journal:  JACC Heart Fail       Date:  2020-06-10       Impact factor: 12.035

7.  Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry.

Authors:  Michele Correale; Adriana Mallardi; Pietro Mazzeo; Lucia Tricarico; Claudia Diella; Valentina Romano; Armando Ferraretti; Alessandra Leopizzi; Giuseppina Merolla; Matteo Di Biase; Natale Daniele Brunetti
Journal:  Int J Cardiol Heart Vasc       Date:  2020-02-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.